


Leveraging the Value of Biobanks to Society: The pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)



Biobanks: Essential Resources for Medical Progress

Collections of tissue specimens and medical data

- Powerful resources for basic and translational biomedical research

Large number of extant small- to mid-size individual collections

- Represent overall an extremely valuable resource, but...

Interoperability value heretofore not leveraged due to


- Lack of inventoried access
- Lack of harmonization and standardization
- Lack of quality control and documentation

BBMRI:

- Sustainable infrastructure to provide integration and access to resources and services
- 53 participants – 222 associated organizations – 33 countries

Biobanks, Biomarkers, and Precision Medicine

From traditional disease definition...




targeted therapies in patient subgroups
→ identify disease mechanism


...to mechanism-based disease definition...

...requires comparative biobank studies across different diseases for clinical trial design and biomarker development

BBMRI: a pan-European Infrastructure



BBMRI: Preparatory Phase Accomplishments



The ERIC Legal Framework



Internationally recognized legal entity


Establishment of operational sites in different Member States that operate under one legislation

VAT exemption

In force since 28.8.2009

ERIC: the New Legal Structure of BBMRI

Distributed hub and spoke structure



BBMRI-ERIC – Current Status

By September 2011:

- 12 Member States signed the MoU:
Austria, Czech Republic, Estonia, Finland, Greece, Italy, Latvia, Malta, Netherlands, Norway, Spain, Sweden
- 3 countries currently finalising signature: France, Germany, Bulgaria
- Ireland, Switzerland, Poland and Turkey to be observers

September 2011:


Ministerial representatives agreed on the details of the **BBMRI-ERIC STATUTES**

Imminent: BBMRI-ERIC application to EC

End of 2012: Target to establish legal status

Expert Centres: Extending BBMRI to PPP

Win-Win for Public and Private Sectors



collaborative research

responsible use of finite resources

data sharing

enhanced innovation

Coordination/Executive Mgmt.

K. Zatloukal, AT; E. Vuorio, FI

M. Yuille, UK; M Pasterk, FR

Population-based Biobanks:

L. Peltonen+, FI/UK; M. Perola, FI

A. Metspalu, EE

Disease-oriented Biobanks:

E. Wichmann, GER, T Meitinger, GER

Biomolecular Resources:

U. Landegren, SE; M. Taussig, UK

Databases & Biocomputing:

J-E Litton, SE

Ethical, Legal and Societal Issues:

A. Cambon-Thomsen, FR

Funding and Financing:

G. Dagher, FR; J. Ridder, NL

C. Brechot, FR;

Governance Council Chair:

L. Peltonen+; E. Vuorio, FI

Advisory Board Chair:

G-J van Ommen, NL

Coordination Board Chair:

K. Zatloukal, AT

Stakeholder Forum Chair:

M. Griffith, IR

